Physician profile
Nora Khatib
NPI 1538487756
$5,418.37
in general payments reported to CMS, 2019-2025
27 companies · $571 in 2025
The $571 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,473 · 2020: $1,511 · 2021: $17.87 · 2022: $510 · 2023: $573 · 2024: $762 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,905.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $1,224.84 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $687.08 | 2019-2023 | |
| Astellas Pharma US INC | $643.41 | 2023-2025 | Izervay |
| Biotronik INC. | $374.97 | 2022-2023 | Acticor 7 Vr-T Dx |
| Eyepoint US, INC. | $296.99 | 2019-2020 | |
| Genentech USA, INC. | $256.96 | 2022-2025 | Vabysmo |
| Oyster Point Pharma, INC. | $175.75 | 2022-2024 | Tyrvaya, Ryzumvi |
| Dutch Ophthalmic, USA | $170.45 | 2019 | |
| Alcon Vision LLC | $160.78 | 2025 | Clareon Panoptix Pro |
| Biotissue Holdings INC. | $155.60 | 2020-2025 | |
| Alnylam Pharmaceuticals INC. | $143.90 | 2025 | Givlaari |
| Regeneron Healthcare Solutions, INC. | $142.86 | 2019-2023 | Eylea Hd |
| Bausch & Lomb Americas INC. | $142.54 | 2022-2024 | Xiidra, Miebo |
| Aerie Pharmaceuticals, INC. | $140.50 | 2019 | |
| Amgen INC. | $131.58 | 2024-2025 | Tepezza |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $123.54 | 2019 | |
| Mallinckrodt Hospital Products INC. | $107.46 | 2023 | Acthar |
| Sight Sciences, INC. | $106.13 | 2022 | |
| Carl Zeiss Meditec, INC. | $57.55 | 2019 | |
| Ani Pharmaceuticals, INC. | $44.14 | 2025 | Iluvien |
| Kedrion Biopharma, INC. | $29.42 | 2025 | Gammaked, Koate, Kedrab |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Allergan, INC. | $18.02 | 2020 | |
| Eyevance Pharmaceuticals LLC | $17.97 | 2019 | |
| Apellis Pharmaceuticals, INC. | $16.04 | 2023 | Syfovre |
| Kala Pharmaceuticals, INC. | $15.50 | 2019 | |
| Shire North American Group INC | $14.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nora Khatib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.